Description
VDBEST M 500 Tablet contains Vildagliptin 50 mg and Metformin 500 mg, a combination of two oral antidiabetic agents used to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a healthcare professional. Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while metformin is a biguanide that helps reduce excessive glucose production by the liver and improves the body’s response to insulin.
This combination may be prescribed when a single medicine does not provide adequate glycaemic control or when a clinician considers combination treatment appropriate. It should be used alongside an individualised diet, physical activity, regular monitoring and medical follow-up.
CardianCare is associated with cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Vildagliptin 50 mg + Metformin 500 mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing details and applicable quality documentation.
For procurement teams evaluating a Vildagliptin 50 mg + Metformin 500 mg Tablets manufacturer and supplier India, important checks include composition accuracy, dosage form, product authorisation, packaging, batch traceability, shelf life and commercial supply terms.
2. Key Ingredient
Composition:
Vildagliptin 50 mg + Metformin 500 mg
Vildagliptin 50 mg: Vildagliptin is a DPP-4 inhibitor that helps prolong the activity of incretin hormones. These hormones contribute to glucose-dependent insulin secretion and help regulate glucagon secretion when blood glucose levels are elevated.
Metformin 500 mg: Metformin is a biguanide antidiabetic agent. It primarily reduces glucose production in the liver and improves insulin sensitivity, helping the body manage blood glucose levels.
Together, these active ingredients act through complementary mechanisms to support glycaemic management in eligible adults with type 2 diabetes. suitability depends on the patient’s clinical condition, kidney and liver function, other medicines and the approved product information.
Businesses researching a Vildagliptin 50 mg + Metformin 500 mg pharmaceutical company India should review product composition, authorised manufacturing source, approved labelling and relevant quality assurance documentation.
Companies looking for a Vildagliptin 50 mg + Metformin 500 mg medicine manufacturer India should verify applicable manufacturing permissions, product authorisation, batch documentation and regulatory compliance before entering into a supply arrangement.
3. Key Benefits
1. Type 2 diabetes management: Helps improve blood glucose control in adults for whom this combination is clinically appropriate.
2. Complementary mechanisms: Combines DPP-4 inhibition with metformin’s effects on liver glucose production and insulin sensitivity.
3. Glucose regulation: Vildagliptin supports glucose-dependent insulin and glucagon regulation.
4. Liver glucose production management: Metformin helps reduce excessive glucose production by the liver.
5. Combination treatment option: May be prescribed when a clinician determines that treatment with both active ingredients is appropriate.
6. Comprehensive diabetes care: Can be part of a treatment plan that includes diet, physical activity, monitoring and regular medical review.
Individual results vary. This medicine does not replace healthy lifestyle measures or professional diabetes care.
Pharmaceutical buyers searching for a Vildagliptin 50 mg + Metformin 500 mg supplier India should verify current availability, product authenticity, storage conditions, shelf life and relevant documentation.
A Vildagliptin 50 mg + Metformin 500 mg Tablet wholesaler and distributor India enquiry may involve stock availability, minimum order quantities, distribution eligibility, delivery coverage and applicable commercial terms.
Businesses looking for a Vildagliptin 50 mg + Metformin 500 mg bulk supplier India should request a formal quotation and confirm packaging specifications, batch traceability, storage requirements and quality documentation.
A Vildagliptin 50 mg + Metformin 500 mg pharmaceutical distributor India should verify the applicable licensing requirements, product authorisation and approved promotional information before beginning commercial distribution.
4. How Does It Work?
Vildagliptin mechanism: Vildagliptin inhibits the DPP-4 enzyme, which normally breaks down incretin hormones such as GLP-1 and GIP. By prolonging incretin activity, it supports glucose-dependent insulin secretion and helps regulate glucagon secretion.
Metformin mechanism: Metformin primarily reduces glucose production in the liver and improves insulin sensitivity in body tissues. This helps reduce excessive glucose release into the bloodstream and supports improved glycaemic control.
The two ingredients act through different but complementary pathways. The risk of low blood glucose can increase when the combination is used with insulin or certain other antidiabetic medicines. Metformin-associated lactic acidosis is rare but serious, with risk increased in certain clinical situations, including significant kidney impairment.
5. Directions for Use
– Dosage: Take only as prescribed by a qualified doctor. The dose and suitability depend on the patient’s treatment history, clinical condition and kidney function.
– Administration: Follow the approved product label and your doctor’s instructions regarding timing and meals. Do not crush or split the Tablet unless the product information permits it.
– Regular timing: Take the medicine consistently according to the prescribed schedule.
– Kidney function: Kidney function should be assessed before and during metformin treatment as clinically indicated. The combination may not be suitable for patients with significant renal impairment.
– Missed dose: Follow the patient leaflet or ask a doctor or pharmacist for advice. Do not take a double dose to make up for a missed dose.
– Lifestyle measures: Continue the recommended dietary plan, physical activity and blood glucose monitoring.
– Medical review: Inform your doctor if you develop persistent vomiting, dehydration, severe illness or other significant symptoms.
Do not independently change the dose or combine this medicine with another product containing the same active ingredients. Follow the approved prescribing information for the exact formulation.
6. Possible Side Effects
Possible side effects associated with vildagliptin and metformin may include:
– Nausea
– Diarrhoea
– Vomiting
– Abdominal discomfort
– Reduced appetite
– Headache or dizziness
Some patients may experience gastrointestinal symptoms, particularly when starting metformin or changing treatment.
Important adverse reactions requiring medical attention:
– Lactic acidosis: A rare but serious metformin-associated complication. Seek urgent medical care for concerning symptoms such as unusual weakness, muscle pain, breathing difficulty, unusual sleepiness or feeling very unwell, particularly during severe illness or dehydration.
– Liver problems: Vildagliptin may require liver function monitoring. Report persistent nausea, unusual fatigue, dark urine or yellowing of the skin or eyes promptly.
– Pancreatitis: Severe, persistent abdominal pain, sometimes radiating to the back, requires urgent medical assessment.
– Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas.
– Allergic reactions: Swelling of the face, lips or throat, breathing difficulty or a severe rash requires emergency care.
This list is not exhaustive. Consult a healthcare professional about persistent or concerning symptoms and refer to the approved product information for a complete adverse-effect profile.
7. Safety Information
– Medical supervision: Use only under the guidance of a qualified healthcare professional.
– Kidney health: Metformin is not suitable for patients with severe renal impairment. Assess kidney function before and during treatment as recommended.
– Liver health: Liver disease and abnormal liver function require clinical assessment. Follow the approved product information for monitoring requirements.
– Lactic acidosis risk: Tell the doctor about kidney problems, severe infection, dehydration, heavy alcohol use or other significant medical conditions that may increase risk.
– Pancreatitis: Discuss any history of pancreatitis with the prescribing doctor.
– Pregnancy and breastfeeding: Seek medical advice before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should assess the most appropriate treatment.
– Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements. Some medicines and contrast procedures may require additional assessment or temporary treatment changes.
– Alcohol: Avoid excessive alcohol consumption and ask your doctor about alcohol use while taking metformin.
– Surgery or medical procedures: Tell the healthcare team that you take metformin, particularly before procedures involving iodinated contrast or situations where food and fluid intake may be restricted.
– Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of reach of children.
– Product verification: Healthcare professionals and pharmaceutical buyers should confirm the exact composition, approved indications, manufacturing source and applicable regulatory documentation before use or procurement.
This information is educational and does not replace approved prescribing information or individual medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare is associated with cardiac and diabetic healthcare products and provides a point of contact for pharmaceutical trade enquiries. Doctors, pharmacists, wholesalers, distributors and eligible business partners should confirm current product availability and commercial arrangements directly with the company.
Businesses researching a Vildagliptin 50 mg + Metformin 500 mg PCD pharma franchise India opportunity can enquire about current product availability, partner eligibility, territory terms and applicable business requirements.
For a Vildagliptin 50 mg + Metformin 500 mg Tablets PCD pharma franchise enquiry, prospective partners can request information about product listings, minimum order requirements, distribution eligibility and any promotional support that may be available.
Companies exploring a Vildagliptin 50 mg + Metformin 500 mg Tablet PCD franchise should confirm whether this product is included in a current programme before making investment or promotional commitments.
Businesses evaluating Vildagliptin 50 mg + Metformin 500 mg third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Due diligence may include manufacturing permissions, product approvals, applicable GMP compliance, minimum batch quantities and quality documentation.
A Vildagliptin 50 mg + Metformin 500 mg Tablet third party manufacturer India enquiry should cover the authorised manufacturing facility, formulation specifications, quality systems, batch release procedures, packaging requirements and contractual responsibilities.
Companies researching Vildagliptin 50 mg + Metformin 500 mg contract manufacturing India should verify service availability directly with the proposed manufacturing partner and review regulatory responsibilities, quality agreements, technical documentation and commercial feasibility.
Contact CardianCare through its official website to enquire about current product availability and eligible pharmaceutical business opportunities. Distribution, franchise and manufacturing arrangements must be confirmed directly with the company before being represented as available services.
For more information about VDBEST M 500 Tablet (Vildagliptin 50 mg + Metformin 500 mg), click here













Reviews
There are no reviews yet.